April 22, 2008 - ... Biocon commences Phase IIb trials for Glioma and NSCLC for BIOMAb EGFR :An open label, prospective, multi-centric study to evaluate the Safety And Efficacy of BIOMAb-EGFR™ (Nimotuzumab) as Induction and Maintenance Therapy in combination with Radiotherapy plus Temozolomide (Concomitant & Adjuvant) in Indian patients with Glioblastoma Multiforme is ongoing at 8 investigational sites across the country.
Another Clinical Trial designed as an open-label, randomized, comparative, multi-centric Study To Assess Safety And Efficacy Of BIOMAb-EGFR™ &Nimotuzumab& in Combination with Chemotherapy Versus Chemotherapy alone in the treatment of Patients with Stage IIIB / IV Non Small Cell Lung Cancer (NSCLC) is also being initiated at 11 sites.
The above Clinical Trials will enable Biocon's Oncotherapeutics division to expand its market share through label extensions... Biocon's Press Release -
